KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Invested Capital (2016 - 2025)

Historic Invested Capital for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to -$156.7 million.

  • Novavax's Invested Capital rose 7023.91% to -$156.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$156.7 million, marking a year-over-year increase of 7023.91%. This contributed to the annual value of -$563.1 million for FY2024, which is 2145.56% up from last year.
  • According to the latest figures from Q3 2025, Novavax's Invested Capital is -$156.7 million, which was up 7023.91% from $37.6 million recorded in Q2 2025.
  • Novavax's Invested Capital's 5-year high stood at $1.0 billion during Q1 2021, with a 5-year trough of -$895.6 million in Q1 2023.
  • In the last 5 years, Novavax's Invested Capital had a median value of -$431.7 million in 2024 and averaged -$278.2 million.
  • As far as peak fluctuations go, Novavax's Invested Capital soared by 24519.17% in 2021, and later crashed by 147098.46% in 2023.
  • Quarter analysis of 5 years shows Novavax's Invested Capital stood at -$351.7 million in 2021, then tumbled by 80.3% to -$634.1 million in 2022, then decreased by 13.07% to -$716.9 million in 2023, then increased by 21.46% to -$563.1 million in 2024, then skyrocketed by 72.18% to -$156.7 million in 2025.
  • Its Invested Capital was -$156.7 million in Q3 2025, compared to $37.6 million in Q2 2025 and -$75.6 million in Q1 2025.